mavacamten

Details

Key Milestones²
Milestones title	Date
Call for patient/clinician input open	August 24, 2022
Call for patient/clinician input closed	October 17, 2022
Clarification: - Patient input submission received from the Canadian Heart Patient Alliance and the HeartLife Foundation
Submission received	September 22, 2022
Submission accepted	October 06, 2022
Review initiated	October 07, 2022
Draft Canada's Drug Agency review report(s) provided to sponsor for comment	January 05, 2023
Deadline for sponsors comments	January 16, 2023
Canada's Drug Agency review report(s) and responses to comments provided to sponsor	February 09, 2023
Expert committee meeting (initial)	February 22, 2023
Draft recommendation issued to sponsor	March 08, 2023
Draft recommendation posted for stakeholder feedback	March 16, 2023
End of feedback period	March 31, 2023
Final recommendation issued to sponsor and drug plans	April 14, 2023
Final recommendation posted	May 03, 2023
Deadline for sponsor to submit redaction requests on draft Canada's Drug Agency review report(s)	May 01, 2023
Canada's Drug Agency review report(s) posted	June 23, 2023

Last Updated : June 23, 2023

nivolumab

Details

Key Milestones²
Milestones title	Date
Call for patient/clinician input open	August 15, 2022
Call for patient/clinician input closed	October 07, 2022
Clarification: - Patient input submission received from Canadian Cancer Society, Lung Cancer Canada
Submission received	September 13, 2022
Submission accepted	September 27, 2022
Review initiated	September 28, 2022
Draft CADTH review report(s) provided to sponsor for comment	December 15, 2022
Deadline for sponsors comments	January 03, 2023
CADTH review report(s) and responses to comments provided to sponsor	January 26, 2023
Expert committee meeting (initial)	February 08, 2023
Draft recommendation issued to sponsor	February 22, 2023
Draft recommendation posted for stakeholder feedback	March 02, 2023
End of feedback period	March 16, 2023
Final recommendation issued to sponsor and drug plans	March 30, 2023
Final recommendation posted	April 18, 2023
Deadline for sponsor to submit redaction requests on draft CADTH review report(s)	April 14, 2023
CADTH review report(s) posted	July 11, 2023

Last Updated : January 29, 2025

brexucabtagene autoleucel

Details

Key Milestones²
Milestones title	Date
Call for patient/clinician input open	10-Aug-22
Call for patient/clinician input closed	30-Sep-22
Clarification: - Patient input submission received from The Leukemia & Lymphoma Society of Canada.
Submission received	15-Sep-22
Submission accepted	29-Sep-22
Review initiated	03-Oct-22
Draft CADTH review report(s) provided to sponsor for comment	19-Dec-22
Deadline for sponsors comments	05-Jan-23
CADTH review report(s) and responses to comments provided to sponsor	26-Jan-23
Expert committee meeting (initial)	08-Feb-23
Draft recommendation issued to sponsor	22-Feb-23
Draft recommendation posted for stakeholder feedback	02-Mar-23
End of feedback period	16-Mar-23
Final recommendation issued to sponsor and drug plans	29-Mar-23
Final recommendation posted	17-Apr-23
Deadline for sponsor to submit redaction requests on draft CADTH review report(s)	13-Apr-23
CADTH review report(s) posted	09-Jun-23

Last Updated : January 27, 2025

ferumoxytol

Details

Key Milestones²
Milestones title	Date
Call for patient/clinician input open	August 03, 2022
Call for patient/clinician input closed	September 23, 2022
Clarification: - Patient input submission received from the Gastrointestinal Society
Submission received	August 31, 2022
Submission accepted	September 15, 2022
Review initiated	September 16, 2022
Draft Canada's Drug Agency review report(s) provided to sponsor for comment	November 30, 2022
Deadline for sponsors comments	December 09, 2022
Canada's Drug Agency review report(s) and responses to comments provided to sponsor	January 13, 2023
Expert committee meeting (initial)	January 25, 2023
Clarification: - CDEC recommendation held pending receipt of NOC and evaluation of the finalized submission requirements. - Withdrawn by the sponsor on 20 Mar 2023

Last Updated : March 20, 2023

difelikefalin

Details

Key Milestones²
Milestones title	Date
Call for patient/clinician input open	03-Aug-22
Call for patient/clinician input closed	23-Sep-22
Clarification: - Patient input submission received from The Kidney Foundation of Canada
Submission received	22-Sep-22
Submission accepted	06-Oct-22
Review initiated	07-Oct-22
Draft Canada's Drug Agency review report(s) provided to sponsor for comment	21-Dec-22
Deadline for sponsors comments	09-Jan-23
Canada's Drug Agency review report(s) and responses to comments provided to sponsor	09-Feb-23
Expert committee meeting (initial)	22-Feb-23
Draft recommendation issued to sponsor	06-Mar-23
Draft recommendation posted for stakeholder feedback	16-Mar-23
End of feedback period	31-Mar-23
Clarification: - Reconsideration: major revisions requested by sponsor
Expert committee meeting	28-Jun-23
Final recommendation issued to sponsor and drug plans	13-Jul-23
Final recommendation posted	31-Jul-23
Deadline for sponsor to submit redaction requests on draft Canada's Drug Agency review report(s)	01-Aug-23
Canada's Drug Agency review report(s) posted	27-Sep-23

Last Updated : April 30, 2024

pegcetacoplan

Details

Key Milestones²
Milestones title	Date
Call for patient/clinician input open	July 28, 2022
Call for patient/clinician input closed	September 19, 2022
Clarification: - Patient input submission received from the Canadian Association of PNH Patients & AAMAC
Submission received	August 26, 2022
Submission accepted	September 12, 2022
Review initiated	September 13, 2022
Draft Canada's Drug Agency review report(s) provided to sponsor for comment	November 29, 2022
Deadline for sponsors comments	December 08, 2022
Canada's Drug Agency review report(s) and responses to comments provided to sponsor	January 13, 2023
Expert committee meeting (initial)	January 25, 2023
Draft recommendation issued to sponsor	February 09, 2023
Draft recommendation posted for stakeholder feedback	February 16, 2023
End of feedback period	March 03, 2023
Final recommendation issued to sponsor and drug plans	March 20, 2023
Final recommendation posted	April 05, 2023
Deadline for sponsor to submit redaction requests on draft Canada's Drug Agency review report(s)	April 03, 2023
Canada's Drug Agency review report(s) posted	May 18, 2023

Last Updated : May 18, 2023

dupilumab

Details

Key Milestones²
Milestones title	Date
Request for Advice received	July 15, 2022
Manufacturer informed of request for advice	July 25, 2022
Manufacturer information or comments due	August 09, 2022
Request for Advice initiated	August 10, 2022
Draft Canada's Drug Agency review report(s) sent to sponsor	October 06, 2022
Deadline for sponsors comments	October 18, 2022
Canada's Drug Agency review report(s) and responses to comments provided to sponsor	November 11, 2022
Expert committee meeting (initial)	November 23, 2022
Expert committee meeting (initial)	November 23, 2022
Draft recommendation posted for stakeholder feedback	December 15, 2022
End of feedback period	January 06, 2023
Final recommendation issued to sponsor and drug plans	January 18, 2023
Final recommendation posted	February 06, 2023
Deadline for sponsor to submit redaction requests on draft Canada's Drug Agency review report(s)	February 02, 2023
Canada's Drug Agency review report(s) posted	April 13, 2023

Last Updated : April 13, 2023

sotorasib

Details

Key Milestones²
Milestones title	Date
Call for patient/clinician input open	July 21, 2022
Call for patient/clinician input closed	September 12, 2022
Clarification: - Patient input submission received from Lung Cancer Canada, Lung Health Foundation, and Canadian Cancer Survivor Network.
Submission received	August 19, 2022
Submission accepted	September 02, 2022
Review initiated	September 06, 2022
Draft CADTH review report(s) provided to sponsor for comment	July 20, 2023
Clarification: - Submission temporarily suspended - Additional information has been received and the temporary suspension of the review has been lifted
Deadline for sponsors comments	July 31, 2023
CADTH review report(s) and responses to comments provided to sponsor	August 31, 2023
Expert committee meeting (initial)	September 13, 2023
Draft recommendation issued to sponsor	September 27, 2023
Draft recommendation posted for stakeholder feedback	October 05, 2023
End of feedback period	October 20, 2023
Clarification: - Reconsideration: major revisions requested by sponsor
Expert committee meeting	February 14, 2024
Final recommendation posted	March 19, 2024
Deadline for sponsor to submit redaction requests on draft CADTH review report(s)	March 14, 2024
CADTH review report(s) posted	July 23, 2024

Last Updated : January 29, 2025

crisantaspase recombinant

Details

Key Milestones²
Milestones title	Date
Call for patient/clinician input open	20-Jul-22
Call for patient/clinician input closed	12-Sep-22
Clarification: - Patient input submission received from The Leukemia & Lymphoma Society of Canada (LLSC).
Submission received	18-Aug-22
Submission accepted	01-Sep-22
Review initiated	02-Sep-22
Draft Canada's Drug Agency review report(s) provided to sponsor for comment	17-Nov-22
Deadline for sponsors comments	28-Nov-22
Canada's Drug Agency review report(s) and responses to comments provided to sponsor	22-Dec-22
Expert committee meeting (initial)	11-Jan-23
Draft recommendation issued to sponsor	24-Jan-23
Draft recommendation posted for stakeholder feedback	02-Feb-23
End of feedback period	16-Feb-23
Clarification: - Reconsideration: major revisions requested by drug programs - Reconsideration accepted
Expert committee meeting	12-Apr-23
Final recommendation issued to sponsor and drug plans	26-Apr-23
Final recommendation posted	15-May-23
Deadline for sponsor to submit redaction requests on draft Canada's Drug Agency review report(s)	11-May-23
Canada's Drug Agency review report(s) posted	12-Jul-23

Last Updated : April 30, 2024

rivaroxaban

Details

Key Milestones²
Milestones title	Date
Call for patient/clinician input open	July 14, 2022
Call for patient/clinician input closed	September 02, 2022
Clarification: - No patient input submission received
Call for industry input open	July 14, 2022
Call for industry input closed	September 02, 2022
Review initiated	October 12, 2022
Expert committee meeting (initial)	August 24, 2023
Draft recommendation posted for stakeholder feedback	-
End of feedback period	October 06, 2023
Final recommendation posted	October 30, 2023
Canada's Drug Agency review report(s) posted	September 21, 2023

Last Updated : October 30, 2024